Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (June 2021)
29 slides from Inhibrx Biosciences's investor presentation, June 2021
Slide 1: Innovation Driven, Outcomes Focused
Innovation Driven Outcomes Focused June 2021
Slide 2: Presentation disclaimer
Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can could differ materially from the plans, intentions and expectations disclosed identify forward-looking statements by the words “will,” “expect,” “intend,” in the forward-looking statements the Compa
Slide 3: Inhibrx at a glance
Inhibrx at a glance VALIDATION FROM INDUSTRY LEADING PARTNERS + Experienced leadership team All platforms and programs + Proven innovation and execution developed in-house with strong patent protection + Ability to precision engineer to specific target biology + Smaller than conventional antibodies
Slide 4: Why invest in Inhibrx?
Why invest in Inhibrx? KEY FINANCIAL HIGHLIGHTS* $108.0M Cash Four differentiated clinical Potential to reach programs with value-creating financial sustainability readouts in 2H 2021/2022 with minimal dilution $20M/Qtr Average rate burn 37.8M Common stock outstanding Backed by solid institutional R
Slide 5: Four differentiated clinical programs
Four differentiated clinical programs Rare diseases Oncology Cell death pathway Immuno-oncology INBRX-101 INBRX-109 INBRX-106 INBRX-105 AAT-Fc fusion protein Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1 x 4-1BB tetravalent + Potential for first meaningful + Single agent activity + Potential
Slide 6: INBRX-101
AAT INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein Fc
Slide 7: Alpha-1 antitrypsin deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) Disease overview ⁺ AATD is an orphan respiratory inherited disease that increases risk of developing pulmonary disease, resulting in progressive loss of lung function and decreased life expectancy ⁺ A small percentage of patients also develop liver disease Curre
Slide 8: Competitive comparison
Competitive comparison 100% Applicable to all patients THERAPIES STATUS 15% Applicable to ~15% of patients with liver issues Aralast THERAPIES STATUS Glassia ARO-AAT Phase 2 Approved Plasma-Derived AAT Prolastin-C DCR-A1AT Phase 2 Zemaira Inhaled AAT Phase 2 Oral Neutrophil Alvelestat Phase 2 Elasta
Slide 9: Our solution
Our solution INBRX-101 proposed standard of care Potential to extend the dosing Engineered to maximize Recombinant manufacturing interval from weekly to every three the functional activity of AAT, provides lower cost of goods, weeks, while maintaining patients particularly in the lung unlimited supp
Slide 10: INBRX-101 Phase 1 trial design
INBRX-101 Phase 1 trial design PART 1 PART 2 Single ascending Multiple ascending dose escalation dose escalation Initiated Initiated N=24 N= 18 N= 6 10 mg/kg N= 6 40 mg/kg N= 6 40 mg/kg N= 6 80 mg/kg* N= 6 80 mg/kg N= 6 120 mg/kg* N= 6 120 mg/kg * bronchial lavage H2 2021 H1 2022 10
Slide 11: INBRX-101: first human data in AATD patients
INBRX-101: first human data in AATD patients PK profile of first 5 patients: 10 mg/kg INBRX-101 10 Preliminary human PK data for first five AATD subjects Serum AAT level (μM) dosed with 10 mg/kg single IV dose of INBRX-101 + Consistent with preclinical estimates 1 + Estimated human half-life is appr
Slide 12: INBRX-109
INBRX-109 Tetravalent DR5 Agonist
Slide 13: Tetravalent DR5 agonist
Tetravalent DR5 agonist DR5: sdAb DR5: sdAb + Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing DR5: sdAb DR5: sdAb ligand (TRAIL) + DR5 activation naturally eliminates damaged and Fc: effector neoplastic cells function disabled 105 kDa 13
Slide 14: INBRX-109 is a best-in-class DR5 agonist
INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) STATUS INBRX-109 Tetravalent 105 Phase II TAS-266 Tetravalent 60 Discontinued1 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 Phase I GEN10292 Dodecavalent 150 ka (2x mAbs) Phase I IGM-8444 Decavalent3 ~950 Phase I Dulanermin
Slide 15: Fast to market opportunity
Fast to market opportunity Chondrosarcoma PFS from placebo-controlled studies Incidence rate of ~1 in 200,000 persons per year Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) Placebo arm PFS 2.9 months ~1,400 cases per year Therapeutic Regorafenib Control arm Placebo Subject nu
Slide 16: INBRX-109 preliminary Phase 1 data in chondrosarcoma
INBRX-109 preliminary Phase 1 data in unresectable or metastatic conventional chondrosarcoma Best Response 3mo 4mo 6mo 9mo 12mo SD (-20%) 62wks ► SD (-7%) 62wks PD SD (-11%) 54wks ► PR (-60%) PD SD (-13%) PD SD (+4%) ► PR (-32%) PD SD (-4%) ** SD (+5%) PD SD (+3%) * SD (-3%) * SD (-4%) * SD (+6%) PD
Slide 17: INBRX-109 Phase 2 registration-enabling study design
INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization INBRX-109 Placebo Conventional chondrosarcoma, grade 2 and 3, unresectable or metastatic N=134* N= 67 * Stratification 3 mg/kg every Until PD or toxicity by line of therapy & Grade three weeks with cross-over Endpoi
Slide 18: Preliminary Phase 1 data: malignant pleural mesothelioma
Preliminary Phase 1 data-malignant pleural mesothelioma, epithelioid subtype Best Response 3mo 4mo 6mo 9mo PART 3 SD (-24%) * SD (-17%) Combination SD (-12%) study PR (-100%) SD (-22%) Mesothelioma with SD (-20%) N=20 Cis-/Carboplatin sd (-12%) & Pemetrexed SD (-5%) SD (-2%) SD (+9%) H1 2022 SD (+13
Slide 19: INBRX-109 on the horizon
INBRX-109 on the horizon FUTURE POTENTIAL PART 3 OPPORTUNITIES Combination studies Solid tumors + IAP antagonists Pancreatic adenocarcinoma Hematologic tumors N=20 2nd line with FOLFIRI Ongoing + Bcl-2 inhibitors Ewing sarcoma NSCLC N=20 with Irinotecan Planned + various combo agents Gastric and col
Slide 20: INBRX-106
INBRX-106 Hexavalent OX40 Agonist
Slide 21: Hexavalent OX40 agonist
Hexavalent OX40 agonist OX40: sdAb OX40: sdAb OX40 is a co-stimulatory receptor on activated T- cells: T T + Provides co-stimulation to activated T-cells OX40: sdAb OX40: sdAb T T + Reverses regulatory T-cell induced immune T sdAb OX40: OX40: sdAb suppression + Enhances T-cell functionality T T T +
Slide 22: INBRX-106 is a best-in-class OX40 agonist
INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hex- IgG1 N Ph 1 (2019) MOXR-0916 Discontinued GSK-3174998 Ph 1 (MM, 2019) BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discont
Slide 23: INBRX-106 Phase 1 trial design
INBRX-106 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Initiated Dose escalation with Initiated Dose expansion Planned dose escalation dose expansion Keytruda™ with Keytruda™ N=20 N= 24 N= 13 N=80 Dose optimization study No pre-screening, all-comers N=20 PD-L1+
Slide 24: INBRX-105
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 25: PD-L1 x 4-1BB multispecific
PD-L1 x 4-1BB multispecific + Designed to provide spatially-restricted PD-L1: sdAb PD-L1: sdAb 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune 4-1BB: sdAb 4-1BB: sdAb cells, 4-1BB signaling promotes prolonged T- cell survival memory formation + Constitutive
Slide 26: INBRX-105 is a best-in-class 4-1BB agonist
INBRX-105 is a best-in-class 4-1BB agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING STATUS INBRX-105 Bivalent/Bivalent No Phase I Gen-1064 Monovalent/Monovalent n/a Phase II MCLA-145 Monovalent/Monovalent Yes Phase I FS222 Bivalent/Bivalent n/a Phase I PRS-343 Bivalent/Bivalent No
Slide 27: INBRX-105 Phase 1 trial design
INBRX-105 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Initiated Dose escalation with Initiated Dose expansion Planned dose escalation dose expansion Keytruda™ with Keytruda™ N=32 N= 32 N= 12 N=80 Single agent: PD-L1+ Basket No pre-screening, all-comers N=20 PD
Slide 28: Near term expected clinical milestones
Near term expected clinical milestones INBRX-109 INBRX-101 INBRX-109 INBRX-109 INBRX-105 (DR5) Initiation (AAT) Initial (DR5) Initial pancreatic (DR5) Ewing (PD-L1 x 41BB) of chondrosarcoma Phase 1 data and mesothelioma sarcoma Keytruda dose registration-enabling trial combination combination expans
Slide 29: 11025 N. Torrey Pines Rd, La Jolla, CA
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com